Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 26, 2015 07:00 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Reports Fourth Quarter 2014 Financial Results

CAMBRIDGE, Mass., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative...
February 19, 2015 08:00 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Biomarker-Selected Clinical Trial of MM-121 in Patients with Heregulin Positive Non-Small Cell Lung Cancer

Trial is recruiting biomarker-selected patients previously treated with two lines of therapy for locally advanced or metastatic disease Merrimack's first study to prospectively select patients...
February 12, 2015 08:00 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Announces Timing of Fourth Quarter 2014 Investor Conference Call

CAMBRIDGE, Mass., Feb. 12, 2015 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Fourth Quarter 2014 Investor Conference Call and...
January 22, 2015 17:00 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Names Birgit M. Schoeberl, Ph.D. as Head of Discovery Division and Announces the Addition of Ulrik B. Nielsen, Ph.D. to Its Board of Directors

CAMBRIDGE, Mass., Jan. 22, 2015 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Birgit M. Schoeberl, Ph.D. has been named the new head of its Discovery division....
January 20, 2015 08:00 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Presents Additional Analyses of Phase 3 MM-398 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium

CAMBRIDGE, Mass., Jan. 20, 2015 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced that additional analyses were presented on January 16, 2015 from the Phase 3 NAPOLI-1 study...
January 08, 2015 08:00 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Announces Oral Presentation of Additional Analyses of MM-398 Phase 3 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium

CAMBRIDGE, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that additional analyses from the Phase 3 NAPOLI-1 study of MM-398 (nanoliposomal...
January 07, 2015 08:00 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President & CEO, is scheduled to present at the 33rd Annual...
December 17, 2014 08:00 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Announces the Addition of Russell T. Ray to Its Board of Directors

CAMBRIDGE, Mass., Dec. 17, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the election of Russell T. Ray to its Board of Directors, effective January 1,...
December 12, 2014 08:00 ET | Source: Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Presents Research on Innovative Pipeline for Patients With Breast Cancer at the 2014 San Antonio Breast Cancer Symposium

CAMBRIDGE, Mass., Dec. 12, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced data from multiple presentations at the 2014 San Antonio Breast Cancer Symposium in...
December 04, 2014 08:00 ET | Source: Merrimack Pharmaceuticals

Video Release -- Preclinical Research Differentiating the Activity of Merrimack's MM-398, Nanoliposomal Irinotecan (nal-IRI), Published in Cancer Research

CAMBRIDGE, Mass., Dec. 4, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that Cancer Research has published the paper "Preclinical Activity of Nanoliposomal...